Desvenlafaxine Tablet, Extended Release
Product Images NDC 68788-8760

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 68788-8760). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Desvenlafaxine Extended-release Tablets 50mg (Desvenlafaxine Tablets 50mg 30s Label)

This information shows details about Desvenlafaxine Extended-Release Tablets 50mg, a generic version of Pristiq. It includes information about dosage, film-coated tablets, and the manufacturer Rubicon Research Private Limited. The tablets are pink, round, and imprinted with an arrowhead symbol. The text also mentions precautions such as keeping the medication out of reach of children and states that it should only be used as prescribed to the specific patient.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 1)

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 2)

This data appears to show changes in pharmacokinetics (PK) due to the presence of CYP3A4 inhibitors, particularly ketoconazole. The geometric mean ratios with their 90% confidence intervals suggest an increase in Cmax values for ketoconazole compared to the reference.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 3)

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 4)

This text provides information on the estimated proportion of patients with relapse over time comparing Desverla 50mg and Placebo. The graph displays the percentage of relapse with a range of 0-150 days after randomization. The data shows that around 40% of patients experienced relapse, with the treatment and placebo groups differentiated.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 5)

This text provides information regarding the estimated proportion of patients with relapse (%) over time (days from randomization) for Desvenlafaxine compared to Placebo. The graph shows data points at 0, 50, 100, and 150 days, with a value of 200 for the estimated proportion of patients with relapse.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.